(HealthDay News) — In a trial of 368 Chinese patients with lupus nephritis, those who were given a trio of medications were more likely to see a complete remission. The researchers, led by Zhihong Liu, MD, of the Nanjing University School of Medicine in China, reported the findings online November 11 in the Annals of Internal Medicine.

Liu’s team randomly assigned patients with lupus nephritis to one of two groups: One received monthly infusions of cyclophosphamide, plus oral steroid medication; the other received oral steroids, along with two immune-suppressing medications – mycophenolate mofetil and tacrolimus.

After six months, 45.9% of patients on the drug trio were in complete remission, and 83.5% had at least a partial response. In contrast, 25.6% of patients on cyclophosphamide were in complete remission. And 63.0% had at least a partial response.

“Multitarget therapy provides superior efficacy compared with intravenous cyclophosphamide as induction therapy for lupus nephritis,” the authors write.

Full Article
Full Text (subscription or payment may be required)